Unihealth Consultancy makes tepid debut on NSE Emerge

| Leave a Comment | IPO

Unihealth Consultancy, a healthcare service provider, made a tepid debut on the NSE Emerge platform on September 21, listing at Rs 135, a 2.2 percent premium over its issue price of Rs 132. The stock was trading at Rs 137.30 at 11.40 am.

The Rs 56.55-crore IPO was entirely a fresh issue of 42.84 lakh shares. It was subscribed 18.22 times, with retail investors bidding 24.61 times the quota of shares allotted to them.

Unihealth Consultancy is based out of Mumbai but has operational presence in multiple countries across Africa. Its business segments include medical centers, hospitals, consultancy services, distribution of pharmaceutical and medical consumable products, and medical value travel.

Under UMC Hospitals, the company operates a combined capacity of 200 operational hospital beds across two multi-specialty facilities in Uganda and Nigeria.

In FY23, the company posted revenue of Rs 46.03 crore, up 21 percent from FY22. Net profit doubled to Rs 7.68 crore from Rs 3.82 crore in the same period. However, Unihealth’s FY21 net profit at Rs 5 crore was greater than FY22.

No analyst covered this SME IPO.


Unihealth Consultancy’s tepid listing can be attributed to a number of factors, including the current volatile market conditions, the lack of analyst coverage, and the company’s relatively small size and scale. However, the company has a number of positives going for it, such as its strong growth potential, its diversified business model, and its focus on the African market.

Investors who are considering investing in Unihealth Consultancy should carefully consider the company’s fundamentals, the current market conditions, and their own risk appetite before making a decision.


Related News

  • 22 Sep

    Samhi Hotels Stock Lists with 6.75% Premium, Analysts Recommend Booking Profits

    Samhi Hotels stock made a weak debut on the stock exchanges, listing at a premium of just 6.75% over the IPO price. Several analysts have recommended booking profits in the stock, citing its loss-making status and negative net worth.

  • 22 Sep

    Signature Global IPO Subscribed 11.88 Times on Final Day

    The Signature Global IPO was subscribed 11.88 times on the final day of bidding. The company will use the proceeds to repay debt and for land acquisitions and general corporate purposes. The IPO is expected to list on October 4, but this may change due to the new timeline of T+3.

  • 22 Sep

    Sai Silks IPO Oversubscribed 4.4 Times on Final Day of Bidding

    Sai Silks IPO was oversubscribed 4.4 times on the final day of bidding, with qualified institutional buyers and high networth individuals supporting the issue on closing day. The net fresh issue proceeds will be utilized by the company mainly for the setting up of 30 new stores, two warehouses, working capital requirements and repaying debts. The trading in its equity shares will commence with effect from October 4, as per the IPO schedule.

  • 22 Sep

    Pharma company Valiant Laboratories to go public on September 27

    Pharma company Valiant Laboratories is going public on September 27 at a price band of Rs 133-140 per share. The company plans to raise Rs 152.46 crore via the IPO. Proceeds will be used to fund the expenditure for setting up a manufacturing facility for speciality chemicals and for working capital requirements and general corporate purposes. Valiant Laboratories is a Mumbai-based API and bulk drug manufacturing company with a focus on Paracetamol. It is owned by the promoters including Dhanvallabh Ventures LLP, which holds 62.5 percent shareholding. Valiant Organics, the listed entity on the BSE and NSE, is the promoter of Dhanvallabh Ventures LLP with 73.15 percent stake.

  • 21 Sep

    Signature Global IPO Subscription Update

    Signature Global's IPO has received decent response from investors so far, with HNIs and retail investors being the most aggressive bidders. However, analysts advise investors to be cautious due to the company's history of losses and the fluctuating nature of the real estate industry.

Leave a Reply

Your email address will not be published. Required fields are marked *